No Link---negotiations ensure quality innovation
Kirkwood 16 — John B. Kirkwood, Professor of Law, Associate Dean for Strategic Planning and Mission at Seattle University School of Law, and Senior Fellow at the American Antitrust Institute, Awarded the Jerry S. Cohen Award for the Best Antitrust Scholarship in 2012, J.D. from Harvard Law School, M.A. in Public Policy from Harvard, “Buyer Power And Healthcare Prices,” Washington Law Review, Volume 91, Pages 253-293, Date Accessed: 8-1
Despite this link, it does not appear that federal negotiation would have a large impact on pharmaceutical innovation. Multiple studies suggest that branded drug manufacturers have been exceptionally profitable in recent years.81 If this is correct, then even if marginal R&D projects became unprofitable, most projects would remain worthwhile. Put differently, if the industry has consistently earned high profits, despite the high failure rate of new drugs,82 then its overall, risk-adjusted return on investment has been above the competitive level. If so, the profitability of many drugs could be reduced significantly without depriving the industry of a competitive return on most R&D.
In addition, profits are unlikely to fall significantly on drugs that have no substitutes. On these drugs—the drugs that matter most to patients— the government’s leverage to obtain discounts would be severely limited. In consequence, the companies’ motivation to develop them would remain largely, if not completely, unchanged. This motivation is likely to be substantial, given the way these drugs are priced. Studies of new cancer drugs have found that drug makers base their prices not on the cost of developing them but on the price of the most similar existing treatment. Indeed, the new price is usually set above the price of the existing treatment, producing a steady escalation of new drug prices.83 Because of the companies’ pricing discretion, the incentive to generate “breakthrough” drugs would remain substantial, even if drug companies were forced to give rebates on all drugs.84 In fact, because federal negotiation would increase the relative profitability of new, unique drugs, it may actually heighten the incentive to develop them.85 Finally, the companies are aided in their search for the next breakthrough drug by the federal government’s extensive support of basic scientific research.86